A Retrospective Study on the Clinical Application of Compound Huangbai Liquid Topical Solution

注册号:

Registration number:

ITMCTR2024000310

最近更新日期:

Date of Last Refreshed on:

2024-08-27

注册时间:

Date of Registration:

2024-08-27

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

复方黄柏液涂剂临床应用的回顾性研究

Public title:

A Retrospective Study on the Clinical Application of Compound Huangbai Liquid Topical Solution

注册题目简写:

English Acronym:

研究课题的正式科学名称:

复方黄柏液涂剂临床应用的回顾性研究

Scientific title:

A Retrospective Study on the Clinical Application of Compound Huangbai Liquid Topical Solution

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

罗文基

研究负责人:

罗文基

Applicant:

Luo Wenji

Study leader:

Luo Wenji

申请注册联系人电话:

Applicant telephone:

+86 139 0253 3429

研究负责人电话:

Study leader's telephone:

+86 139 0253 3429

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1018693996@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1018693996@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广东省珠海市香洲区梅华东路52号

研究负责人通讯地址:

广东省珠海市香洲区梅华东路52号

Applicant address:

No. 52, Meihua East Road, Xiangzhou District, Zhuhai City, Guangdong Province

Study leader's address:

No. 52, Meihua East Road, Xiangzhou District, Zhuhai City, Guangdong Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中山大学附属第五医院

Applicant's institution:

The Fifth Affiliated Hospital of Sun Yat-sen University

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

中大五院[2024]伦字第(K143-1)号

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

中山大学附属第五医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee, The Fifth Affiliated Hospital of Sun Yat-sen University

伦理委员会批准日期:

Date of approved by ethic committee:

2024/5/24 0:00:00

伦理委员会联系人:

温盛霖

Contact Name of the ethic committee:

Wen Shenglin

伦理委员会联系地址:

广东省珠海市香洲区梅华东路52号中山大学附属第五医院行政综合楼301

Contact Address of the ethic committee:

Room 301, Administrative Complex Building, The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Xiangzhou District, Zhuhai City, Guangdong Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 756 252 8895

伦理委员会联系人邮箱:

Contact email of the ethic committee:

1018693996@qq.com

研究实施负责(组长)单位:

中山大学附属第五医院

Primary sponsor:

The Fifth Affiliated Hospital of Sun Yat-sen University

研究实施负责(组长)单位地址:

广东省珠海市香洲区梅华东路52号

Primary sponsor's address:

No. 52, Meihua East Road, Xiangzhou District, Zhuhai City, Guangdong Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

珠海市

Country:

CHINA

Province:

Guangdong province

City:

zhuhai city

单位(医院):

中山大学附属第五医院

具体地址:

广东省珠海市香洲区梅华东路52号

Institution
hospital:

The Fifth Affiliated Hospital of Sun Yat-sen University

Address:

No. 52, Meihua East Road, Xiangzhou District, Zhuhai City, Guangdong Province

经费或物资来源:

山东汉方制药有限公司

Source(s) of funding:

Shandong Hanfang Pharmaceutical Co., Ltd

研究疾病:

多种不同疾病

研究疾病代码:

Target disease:

Multiple different diseases

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

病例研究

Case study

研究所处阶段:

Study phase:

上市后药物

Post-marketing clinical trial

研究目的:

通过回顾性收集使用复方黄柏液涂剂患者的病历信息,分析复方黄柏液涂剂的临床用药特点,评估复方黄柏液涂剂对不同诊断患者的改善作用,总结复方黄柏液涂剂人用经验证据。

Objectives of Study:

The clinical information of patients using compound Phellodenticle liquid coating was retrospectively collected, the clinical characteristics of compound Phellodenticle liquid coating were analyzed, the improvement effects of compound Phellodenticle liquid coating on patients with different diagnoses were evaluated, and the empirical evidence for human use of compound Phellodenticle liquid coating was summarized.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.在目标中心:处方使用复方黄柏液涂剂的病例; 2.年龄在18~80岁,男女不限。

Inclusion criteria

1. In the target center: cases of prescription using compound Phellodiscus liquid coating; 2. Age 18-80 years old, male or female.

排除标准:

研究者认为影响对研究药物的评价,不适合收集的病例。

Exclusion criteria:

The researchers believe that the evaluation of the drug under study is not suitable for the collection of cases.

研究实施时间:

Study execute time:

From 2024-05-01

To      2025-08-31

征募观察对象时间:

Recruiting time:

From 2024-06-01

To      2025-08-31

干预措施:

Interventions:

组别:

复方黄柏液涂剂单药组

样本量:

10000

Group:

Compound Huangbai liquid coating single drug group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

样本总量 Total sample size : 10,000

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东省

市(区县):

深圳

Country:

CHINA

Province:

Guangdong province

City:

shenzhen city

单位(医院):

深圳市龙岗区中医院

单位级别:

三甲

Institution/hospital:

Shenzhen Longgang District Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

云南省

市(区县):

大理市

Country:

China

Province:

yunnan Province

City:

dali city

单位(医院):

大理市第一人民医院

单位级别:

三甲

Institution/hospital:

Dali First People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江苏省

市(区县):

江阴市

Country:

CHINA

Province:

Jiangsu Province

City:

jiangyin city

单位(医院):

江阴市人民医院

单位级别:

三甲

Institution/hospital:

Jiangyin People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东省

市(区县):

珠海市

Country:

CHINA

Province:

Guangdong province

City:

zhuhai city

单位(医院):

中山大学附属第五医院

单位级别:

三甲

Institution/hospital:

The Fifth Affiliated Hospital of Sun Yat-sen University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东省

市(区县):

广州市

Country:

CHINA

Province:

Guangdong province

City:

Guangzhou city

单位(医院):

广州中医药大学深圳医院(福田)

单位级别:

三甲

Institution/hospital:

Shenzhen Hospital of Guangzhou University of Chinese Medicine (Futian)

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东省

市(区县):

广州市

Country:

CHINA

Province:

Guangdong province

City:

Guangzhou city

单位(医院):

广州医科大学附属市八医院

单位级别:

三甲

Institution/hospital:

The Eighth Affiliated Hospital of Guangzhou Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江苏省

市(区县):

无锡市

Country:

CHINA

Province:

Jiangsu Province

City:

wuxi city

单位(医院):

无锡妇幼保健院

单位级别:

三甲

Institution/hospital:

Wuxi maternal and Child Health Care Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东省

市(区县):

佛山市

Country:

CHINA

Province:

Guangdong province

City:

foshan city

单位(医院):

暨南大学附属顺德医院

单位级别:

三甲

Institution/hospital:

Jinan University Affiliated Shunde Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

创面水肿程度评分、疼痛评分、创面愈合时间

指标类型:

次要指标

Outcome:

Score of wound edema degree pain score and wound healing time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规、血清降钙素原(PCT)、白细胞介素(IL)-6、C反应蛋白等其他检查

指标类型:

主要指标

Outcome:

Blood routine serum procalcitonin (PCT) interleukin-6 (IL-6) C-reactive protein and other tests

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

不涉及

Randomization Procedure (please state who generates the random number sequence and by what method):

None

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

http://www.medresman.org.cn/uc/index.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://www.medresman.org.cn/uc/index.aspx

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above